Prevalence and Characteristics of Interstitial Lung Disease Among Patients With Inflammatory Bowel Disease

Amarilys Alarcon-Calderon; Modi Pranav; Felix Wireko; Salma Abdulla; Livia Kruger; Emily Liu; Phillip Schulte; Jay Ryu; Misbah Baqir

doi:10.36141/svdld.2026.18654

Authors

Amarilys Alarcon-Calderon Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA https://orcid.org/0000-0003-2129-2359
Modi Pranav Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA, Department of Internal Medicine, North Mississippi Medical Center, Tupelo, MS, USA
Felix Wireko Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA
Salma Abdulla Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA
Livia Kruger Department of Radiology, Mayo Clinic, Rochester, MN, USA
Emily Liu Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.
Phillip Schulte Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.
Jay Ryu Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA
Misbah Baqir Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA

Keywords:

Bronchiectasis, INTERSTITIAL PNEUMONIA , Interstitial lung disease, Pulmonary fibrosis, Pulmonary function test

Abstract

Background: Inflammatory bowel disease (IBD) is a disorder with extraintestinal manifestations that may involve multiple organ systems. Interstitial lung disease (ILD) is an extraintestinal manifestation that remains underrecognized, and its prevalence, clinical characteristics, and risk factors in IBD are poorly defined.

Methods: We conducted a retrospective study of adults (≥18 years) with IBD who had at least 1 clinical encounter at our hospital between January 1, 2013, and December 31, 2023. IBD and ILD diagnoses were identified by using International Classification of Diseases, Ninth [or Tenth] Revision, Clinical Modification codes, and ILD diagnoses were confirmed by a thoracic radiologist. Demographic and clinical characteristics were abstracted from the electronic health record. Associations between patient characteristics and ILD were evaluated with 2 analyses: cross-sectional cohort and matched case-control. Risk of death was assessed by using a Cox proportional hazards model with ILD as a time-dependent covariate.

Results: Among 875 patients with IBD, 109 (12%) had ILD. Radiographic patterns of ILD most commonly showed nonspecific interstitial pneumonia (27%), indeterminate (26%), and usual interstitial pneumonia (24%). Pulmonary function testing most commonly showed restriction (59%) and impaired diffusing capacity (61%). The cohort analysis showed that higher BMI, bronchiectasis, history of smoking, and use of adalimumab or infliximab were independently associated with ILD. The case-control analysis confirmed these findings and identified older age as another significant factor. ILD was associated with a higher risk of death (hazard ratio, 3.78; 95% CI, 2.50-5.72; P<.001).

Conclusion: ILD in patients with IBD was associated with various clinical characteristics and a higher risk of death. These findings highlight the need for early identification, routine respiratory assessment, and multidisciplinary management.

References

1. Chang JT. Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med. 2020;383(27):2652–2664.

2. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11(46):7227–7236.

3. Algaba A, Guerra I, Ricart E, et al. Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry. Dig Dis Sci. 2021;66(6):2014–2023.

4. Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021;161(4):1118–1132.

5. Kilic Y, Kamal S, Jaffar F, Sriranganathan D, Quraishi MN, Segal JP. Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2024;30(2):230–239.

6. Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239–254.

7. Vaezi A, Ashby T, Schweitzer M, Ghali P, Mirsaeidi M. Interstitial Lung Disease as an Emerging Contributor to Mortality in Patients With Inflammatory Bowel Disease: A Population-Based Epidemiological Study. Clin Transl Gastroenterol. 2024;15(9):e1.

8. Isene R, Bernklev T, Hoie O, et al. Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50(3):300–305.

9. Cheng K, Faye AS. Venous thromboembolism in inflammatory bowel disease. World J Gastroenterol. 2020;26(12):1231–1241.

10. Ghosh S, Deshwal H, Haraf R, et al. Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies. CHEST Pulmonary. 2023;1(3).

11. Higenbottam T, Cochrane GM, Clark TJ, Turner D, Millis R, Seymour W. Bronchial disease in ulcerative colitis. Thorax. 1980;35(8):581–585.

12. Butland RJ, Cole P, Citron KM, Turner-Warwick M. Chronic bronchial suppuration and inflammatory bowel disease. Q J Med. 1981;50(197):63–75.

13. Abu-Hijleh M, Evans S, Aswad B. Pleuropericarditis in a patient with inflammatory bowel disease: a case presentation and review of the literature. Lung. 2010;188(6):505–510.

14. Lu S, Wang L, Zhang W, et al. Ulcerative colitis with acute pleurisy: A case report and review of the literature. Medicine (Baltimore). 2017;96(30):e7630.

15. Cassius De Linval Q, Barat M, Aissaoui M, et al. Imaging findings of thoracic manifestations of Crohn's disease and ulcerative colitis. Insights Imaging. 2024;15(1):197.

16. El-Kersh K, Fraig M, Cavallazzi R, Saad M, Perez RL. Pulmonary necrobiotic nodules in Crohn's disease: a rare extra-intestinal manifestation. Respir Care. 2014;59(12):e190–192.

17. Storch I, Rosoff L, Katz S. Sarcoidosis and inflammatory bowel disease. J Clin Gastroenterol. 2001;33(4):345.

18. Peng YH, Liao WC, Su CH, et al. Association of inflammatory bowel disease with asthma risk: A nationwide cohort study. Allergy Asthma Proc. 2015;36(5):e92–98.

19. Pemmasani G, Loftus EV, Tremaine WJ. Prevalence of Pulmonary Diseases in Association with Inflammatory Bowel Disease. Dig Dis Sci. 2022;67(11):5187–5194.

20. Mumtaz S, Valecha J, Hochwald A, Berianu F, Majithia V, Abril A. Investigating the concomitance of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides and inflammatory bowel disease (IBD). Semin Arthritis Rheum. 2024;66:152452.

21. Humbert S, Guilpain P, Puechal X, et al. Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibody-associated vasculitides: 11 retrospective cases from the French Vasculitis Study Group. Rheumatology (Oxford). 2015;54(11):1970–1975.

22. Yi J, Wu S, He H. Causal association of inflammatory bowel disease with sarcoidosis and the mediating role of primary biliary cholangitis. Front Immunol. 2024;15:1448724.

23. Kisiel MA, Sedvall M, Malinovschi A, et al. Inflammatory bowel disease and asthma. Results from the RHINE study. Respir Med. 2023;216:107307.

24. Kochar B, Sun J, Olen O, et al. Inflammatory bowel disease patients are at increased risk for interstitial lung diseases. Am J Gastroenterol. 2025.

25. Eliadou E, Moleiro J, Ribaldone DG, et al. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. J Crohns Colitis. 2020;14(4):480–489.

26. Mahadeva R, Walsh G, Flower CD, Shneerson JM. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J. 2000;15(1):41–48.

27. Caccaro R, Savarino E, D'Inca R, Sturniolo GC. Noninfectious interstitial lung disease during infliximab therapy: case report and literature review. World J Gastroenterol. 2013;19(32):5377–5380.

28. Patel D, Madani S, Patel S, Guglani L. Review of pulmonary adverse effects of infliximab therapy in Crohn's disease. Expert Opin Drug Saf. 2016;15(6):769–775.

29. Salerno SM, Ormseth EJ, Roth BJ, Meyer CA, Christensen ED, Dillard TA. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis. Chest. 1996;110(2):556–559.

30. Hayek AJ, Pfanner TP, White HD. Inflammatory bowel disease of the lung: The role of infliximab? Respir Med Case Rep. 2015;15:85–88.

31. Valentin S, Renel B, Manneville F, et al. Prevalence of and Factors Associated with Respiratory Symptoms Among Patients with Inflammatory Bowel Disease: A Prospective Study. Inflamm Bowel Dis. 2023;29(2):207–216.

32. Lee CT, Gandhi SA, Elmrayed S, et al. Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis. Thorax. 2025;80(12):918–926.

33. Wood DE, Kazerooni EA, Baum SL, et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(4):412–441.

34. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155(1):242–248.

35. Hotermans G, Benard A, Guenanen H, Demarcq-Delerue G, Malart T, Wallaert B. Nongranulomatous interstitial lung disease in Crohn's disease. Eur Respir J. 1996;9(2):380–382.

36. Casey MB, Tazelaar HD, Myers JL, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol. 2003;27(2):213–219.

37. Mateer SW, Maltby S, Marks E, et al. Potential mechanisms regulating pulmonary pathology in inflammatory bowel disease. J Leukoc Biol. 2015;98(5):727–737.

38. Cavalli CAM, Gabbiadini R, Dal Buono A, et al. Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections. J Clin Med. 2023;12(19).

39. Luo Q, Zhou P, Chang S, Huang Z, Zhu Y. The gut-lung axis: Mendelian randomization identifies a causal association between inflammatory bowel disease and interstitial lung disease. Heart Lung. 2023;61:120–126.

40. Zeng Q, Jiang D. Global trends of interstitial lung diseases from 1990 to 2019: an age-period-cohort study based on the Global Burden of Disease study 2019, and projections until 2030. Front Med (Lausanne). 2023;10:1141372.

41. Abdallah T, Abdallah M, Saifan C, El Sayegh D, Chalhoub M, Sasso L. Hemidiaphragm paresis and granulomatous pneumonitis associated with adalimumab: a case report. Heart Lung. 2014;43(1):84–86.